BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376:103-111. [PMID: 20605202 DOI: 10.1016/s0140-6736(10)60746-5] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Retnakaran R, Ye C, Emery A, Kramer CK, Zinman B. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33867-9] [Reference Citation Analysis]
2 Drucker DJ. Bernard Zinman: A Canadian Clinician Scientist Changing the Management of Diabetes. Diabetes Care 2022;45:1709-14. [DOI: 10.2337/dci22-0017] [Reference Citation Analysis]
3 Blonde L, Umpierrez GE, Reddy SS, Mcgill JB, Berga SL, Bush M, Chandrasekaran S, Defronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Timmons and J, Boyle J. Metformin. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch2] [Reference Citation Analysis]
5 Fisher M. Glitazones and Glitazars. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch12] [Reference Citation Analysis]
6 Kudo T, Zhao ML, Kovary K, Lagory EL, Covert MW, Teruel MN. A dynamic HIF1α- PPARγ circuit controls a paradoxical adipocyte regulatory landscape.. [DOI: 10.1101/2022.05.17.492374] [Reference Citation Analysis]
7 Jonas DE, Crotty K, Yun JDY, Middleton JC, Feltner C, Taylor-Phillips S, Barclay C, Dotson A, Baker C, Balio CP, Voisin CE, Harris RP. Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021;326:744-60. [PMID: 34427595 DOI: 10.1001/jama.2021.10403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
8 Phillips J, Chen JHC, Ooi E, Prunster J, Lim WH. Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure. Front Clin Diabetes Healthc 2021;2. [DOI: 10.3389/fcdhc.2021.731574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kaur H, Kaur A, Kumar Prashar P, Gautam A, Sood A, Kumar Singh S, Gulati M, Kumar Pandey N, Kumar B. Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy. RJPT 2021. [DOI: 10.52711/0974-360x.2021.00603] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Liu X, Zhang Y, Liang H, Xu Y. Overexpression of microRNA-216a-3p Accelerates the Inflammatory Response in Cardiomyocytes in Type 2 Diabetes Mellitus by Targeting IFN-α2. Front Endocrinol (Lausanne) 2020;11:522340. [PMID: 33329376 DOI: 10.3389/fendo.2020.522340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Naveed A, Farrukh L, Sana MK, Naveed B, Randhawa FA. Pharmacological Primary Prevention of Diabetes Mellitus Type II: A Narrative Review. Cureus 2020;12:e10033. [PMID: 32999773 DOI: 10.7759/cureus.10033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Espinoza SE, Musi N, Wang CP, Michalek J, Orsak B, Romo T, Powers B, Conde A, Moris M, Bair-Kelps D, Li Y, Ganapathy V, Jergensen TE, Kelly LC, Jiwani R. Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes. J Gerontol A Biol Sci Med Sci 2020;75:102-9. [PMID: 30888034 DOI: 10.1093/gerona/glz078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
13 Adriana Stoica R, Simona Ștefan D, Rizzo M, Iulia Suceveanu A, Paul Suceveanu A, Serafinceanu C, Pantea-stoian A. Metformin Indications, Dosage, Adverse Reactions, and Contraindications. Metformin 2020. [DOI: 10.5772/intechopen.88675] [Reference Citation Analysis]
14 Sallar A, Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: State of the science. Exp Biol Med (Maywood) 2020;245:889-96. [PMID: 32212859 DOI: 10.1177/1535370220915644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
15 Carlisle BG. Non-existent ClinicalTrials.gov identifiers in abstracts indexed by PubMed.. [DOI: 10.1101/2020.02.24.20027300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ming Y, Yin Y, Sun Z. Interaction of Nuclear Receptor Subfamily 4 Group A Member 1 (Nr4a1) and Liver Linase B1 (LKB1) Mitigates Type 2 Diabetes Mellitus by Activating Monophosphate-Activated Protein Kinase (AMPK)/Sirtuin 1 (SIRT1) Axis and Inhibiting Nuclear Factor-kappa B (NF-κB) Activation. Med Sci Monit 2020;26:e920278. [PMID: 31939452 DOI: 10.12659/MSM.920278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
17 Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2019;12:CD008558. [PMID: 31794067 DOI: 10.1002/14651858.CD008558.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
18 Knowler WC, Crandall JP. Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Curr Diab Rep 2019;19:154. [PMID: 31792721 DOI: 10.1007/s11892-019-1268-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Harreiter J, Roden M. [Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)]. Wien Klin Wochenschr 2019;131:6-15. [PMID: 30980151 DOI: 10.1007/s00508-019-1450-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 18.0] [Reference Citation Analysis]
20 Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circ Res 2018;122:1135-50. [PMID: 29650631 DOI: 10.1161/CIRCRESAHA.118.311912] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
21 Sheng Z, Cao JY, Pang YC, Xu HC, Chen JW, Yuan JH, Wang R, Zhang CS, Wang LX, Dong J. Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2019;10:455. [PMID: 31354627 DOI: 10.3389/fendo.2019.00455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
22 Yamaoka K, Nemoto A, Tango T. Comparison of the Effectiveness of Lifestyle Modification with Other Treatments on the Incidence of Type 2 Diabetes in People at High Risk: A Network Meta-Analysis. Nutrients 2019;11:E1373. [PMID: 31248094 DOI: 10.3390/nu11061373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
23 Parast L, Cai T, Tian L. Using a surrogate marker for early testing of a treatment effect. Biometrics 2019;75:1253-63. [PMID: 31009073 DOI: 10.1111/biom.13067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Weinstock RS, Braffett BH, McGuigan P, Larkin ME, Grover NB, Walders-Abramson N, Laffel LM, Chan CL, Chang N, Schwartzman BE, Barajas RA, Celona-Jacobs N, Haymond MW; TODAY Study Group. Self-Monitoring of Blood Glucose in Youth-Onset Type 2 Diabetes: Results From the TODAY Study. Diabetes Care 2019;42:903-9. [PMID: 30833375 DOI: 10.2337/dc18-1854] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Liu Y, Hu X, Shan X, Chen K, Tang H. Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway. Cancer Cell Int 2019;19:13. [PMID: 30651718 DOI: 10.1186/s12935-019-0732-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
26 Brannick B, Dagogo-Jack S. Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. Endocrinol Metab Clin North Am 2018;47:33-50. [PMID: 29407055 DOI: 10.1016/j.ecl.2017.10.001] [Cited by in Crossref: 91] [Cited by in F6Publishing: 105] [Article Influence: 30.3] [Reference Citation Analysis]
27 Fagg J, Valabhji J. How do we identify people at high risk of Type 2 diabetes and help prevent the condition from developing? Diabet Med 2019;36:316-25. [PMID: 30466172 DOI: 10.1111/dme.13867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
28 Aroda VR, Ratner RE. Metformin and Type 2 Diabetes Prevention. Diabetes Spectr 2018;31:336-42. [PMID: 30510389 DOI: 10.2337/ds18-0020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
29 Xiang AH, Trigo E, Martinez M, Katkhouda N, Beale E, Wang X, Wu J, Chow T, Montgomery C, Nayak KS, Hendee F, Buchanan TA; RISE Consortium., RISE Collaborators. Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care 2018;41:2544-51. [PMID: 30282699 DOI: 10.2337/dc18-1662] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
30 Ordered Categorical Outcomes. Sample Sizes for Clinical, Laboratory and Epidemiology Studies 2018. [DOI: 10.1002/9781118874905.ch4] [Reference Citation Analysis]
31 Survival Time Outcomes. Sample Sizes for Clinical, Laboratory and Epidemiology Studies 2018. [DOI: 10.1002/9781118874905.ch7] [Reference Citation Analysis]
32 Cumulative References. Sample Sizes for Clinical, Laboratory and Epidemiology Studies 2018. [DOI: 10.1002/9781118874905.refs] [Reference Citation Analysis]
33 Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, Zhu D, Chen L, Chen L, Guo L, Guo X, Ji Q, Li Q, Li X, Liu J, Ran X, Shan Z, Shi L, Song G, Yang L, Yang Y, Yang W; Chinese Diabetes Society. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev 2016;32:442-58. [PMID: 27464265 DOI: 10.1002/dmrr.2827] [Cited by in Crossref: 187] [Cited by in F6Publishing: 204] [Article Influence: 46.8] [Reference Citation Analysis]
34 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_16-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Perreault L. Prevention of Type 2 Diabetes. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_2] [Reference Citation Analysis]
36 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_16] [Reference Citation Analysis]
37 Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KMV, Ali MK. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017;177:1808-17. [PMID: 29114778 DOI: 10.1001/jamainternmed.2017.6040] [Cited by in Crossref: 167] [Cited by in F6Publishing: 173] [Article Influence: 33.4] [Reference Citation Analysis]
38 Chuang HC, Wang JS, Lee IT, Sheu WH, Tan TH. Epigenetic regulation of HGK/MAP4K4 in T cells of type 2 diabetes patients. Oncotarget 2016;7:10976-89. [PMID: 26918832 DOI: 10.18632/oncotarget.7686] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
39 Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL. The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord 2016;17:5-17. [PMID: 26956847 DOI: 10.1007/s11154-016-9345-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
40 Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017;60:1601-11. [PMID: 28770322 DOI: 10.1007/s00125-017-4361-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 17.6] [Reference Citation Analysis]
41 Avgerinos K, Tziomalos K. Effects of glucose-lowering agents on ischemic stroke. World J Diabetes 2017; 8(6): 270-277 [PMID: 28694927 DOI: 10.4239/wjd.v8.i6.270] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 2016;241:1323-31. [PMID: 27302176 DOI: 10.1177/1535370216654227] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
43 Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs 2017;77:247-64. [PMID: 28155046 DOI: 10.1007/s40265-017-0694-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
44 Dagogo-jack S. Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. Diabetes Mellitus in Developing Countries and Underserved Communities 2017. [DOI: 10.1007/978-3-319-41559-8_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 He T, Geng J, Zhang Z. Diabetics and Stroke. Translational Medicine Research 2017. [DOI: 10.1007/978-981-10-5804-2_9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Ghaffari-Cherati M, Mahrooz A, Hashemi-Soteh MB, Hosseyni-Talei SR, Alizadeh A, Nakhaei SM. Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: Association with response to metformin. J Res Med Sci 2016;21:92. [PMID: 28163738 DOI: 10.4103/1735-1995.192508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
47 Naidoo P, Wing J, Rambiritch V. Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study. JMIR Res Protoc 2016;5:e145. [PMID: 27491324 DOI: 10.2196/resprot.5073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
48 Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs 2015;75:1071-94. [PMID: 26059289 DOI: 10.1007/s40265-015-0416-8] [Cited by in Crossref: 143] [Cited by in F6Publishing: 109] [Article Influence: 23.8] [Reference Citation Analysis]
49 Yan Q, Li X, Feng B. The efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP). BMC Endocr Disord 2015;15:74. [PMID: 26626301 DOI: 10.1186/s12902-015-0071-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
50 Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 [PMID: 26464759 DOI: 10.4239/wjd.v6.i12.1207] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
51 Suissa S. The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research. Rambam Maimonides Med J 2015;6. [PMID: 26241223 DOI: 10.5041/RMMJ.10218] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
52 Aroda VR, Getaneh A. Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab 2015;10:381-98. [PMID: 30293496 DOI: 10.1586/17446651.2015.1054280] [Reference Citation Analysis]
53 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. SEMERGEN - Medicina de Familia 2015;41:266-78. [DOI: 10.1016/j.semerg.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
54 Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-76. [PMID: 25249668 DOI: 10.2337/dc14-0817] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
55 Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J 2014;18:88-93. [PMID: 25102521 DOI: 10.7812/TPP/14-002] [Cited by in Crossref: 108] [Cited by in F6Publishing: 116] [Article Influence: 15.4] [Reference Citation Analysis]
56 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía JC, Fornos JA, Girbés J, Rica I. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. Avances en Diabetología 2015;31:89-101. [DOI: 10.1016/j.avdiab.2014.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
57 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 243] [Cited by in F6Publishing: 256] [Article Influence: 34.7] [Reference Citation Analysis]
58 Kramer CK, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R. Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum. Diabetologia 2015;58:1354-62. [PMID: 25762205 DOI: 10.1007/s00125-015-3551-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
59 Abdul-ghani M, Defronzo RA, Eldor R. Combination therapy in type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch46] [Reference Citation Analysis]
60 Mata-Cases M, Artola S, Escalada J, Ezkurra-Loyola P, Ferrer-García JC, Fornos JA, Girbés J, Rica I; Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. [Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. Aten Primaria 2015;47:456-68. [PMID: 25735589 DOI: 10.1016/j.aprim.2014.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
61 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society. Revista Clínica Española (English Edition) 2015;215:117-29. [DOI: 10.1016/j.rceng.2014.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
62 Ji L, Zinman B, Patel S, Ji J, Bailes Z, Thiemann S, Seck T. Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial. Adv Ther 2015;32:201-15. [PMID: 25805187 DOI: 10.1007/s12325-015-0195-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
63 Piatti P, Setola E, Galluccio E, Costa S, Fontana B, Stuccillo M, Crippa V, Cappelletti A, Margonato A, Bosi E, Monti LD. Smoking is associated with impaired glucose regulation and a decrease in insulin sensitivity and the disposition index in first-degree relatives of type 2 diabetes subjects independently of the presence of metabolic syndrome. Acta Diabetol 2014;51:793-9. [PMID: 24934227 DOI: 10.1007/s00592-014-0599-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
64 Mogul HR, Freeman R, Nguyen K, Frey M, Klein LA, Jozak S, Tanenbaum K. Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain. PLoS One 2014;9:e108264. [PMID: 25259787 DOI: 10.1371/journal.pone.0108264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
65 Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-8. [PMID: 25249651 DOI: 10.2337/dc14-0893] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 11.4] [Reference Citation Analysis]
66 Pittas AG, Dawson-Hughes B, Sheehan PR, Rosen CJ, Ware JH, Knowler WC, Staten MA; D2d Research Group. Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. Diabetes Care 2014;37:3227-34. [PMID: 25205139 DOI: 10.2337/dc14-1005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
67 Asai A, Nakagawa K, Higuchi O, Kimura T, Kojima Y, Kariya J, Miyazawa T, Oikawa S. Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig 2011;2:318-23. [PMID: 24843505 DOI: 10.1111/j.2040-1124.2011.00101.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 8.3] [Reference Citation Analysis]
68 DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S127-S138. [PMID: 23882037 DOI: 10.2337/dcs13-2011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 187] [Article Influence: 21.4] [Reference Citation Analysis]
69 Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36 Suppl 2:S162-74. [PMID: 23882042 DOI: 10.2337/dcS13-2003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 9.1] [Reference Citation Analysis]
70 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
71 Schulze MB, Hu FB. Epidemiology of Diabetes. Handbook of Epidemiology 2014. [DOI: 10.1007/978-0-387-09834-0_66] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068-1083. [PMID: 24315620 DOI: 10.1016/s0140-6736(13)62154-6] [Cited by in Crossref: 942] [Cited by in F6Publishing: 990] [Article Influence: 104.7] [Reference Citation Analysis]
73 Ransom T, Goldenberg R, Mikalachki A, Prebtani AP, Punthakee Z. Réduction du risque de diabète. Canadian Journal of Diabetes 2013;37:S377-S380. [DOI: 10.1016/j.jcjd.2013.07.033] [Reference Citation Analysis]
74 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013;36:3607-3612. [PMID: 24062330 DOI: 10.2337/dc13-0520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
75 García de la Torre N, Durán A, Del Valle L, Fuentes M, Barca I, Martín P, Montañez C, Perez-Ferre N, Abad R, Sanz F, Galindo M, Rubio MA, Calle-Pascual AL. Early management of type 2 diabetes based on a SMBG strategy: the way to diabetes regression--the St Carlos study : a 3-year, prospective, randomized, clinic-based, interventional study with parallel groups. Acta Diabetol 2013;50:607-14. [PMID: 23532298 DOI: 10.1007/s00592-013-0467-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
76 Wang Z, Wang J, Chan P. Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbs. Evid Based Complement Alternat Med 2013;2013:343594. [PMID: 23737828 DOI: 10.1155/2013/343594] [Cited by in Crossref: 31] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
77 Kabadi UM. Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes. JDM 2013;03:129-133. [DOI: 10.4236/jdm.2013.33019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Suvag S, Utzschneider KM, Kahn SE. Treatment with Thiazolidinediones. The Metabolic Syndrome 2013. [DOI: 10.1007/978-3-7091-1331-8_9] [Reference Citation Analysis]
79 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
80 Griffing GT. New Therapies for Diabetes Mellitus. Pathy's Principles and Practice of Geriatric Medicine 2012. [DOI: 10.1002/9781119952930.ch102] [Reference Citation Analysis]
81 Karam JG, Mcfarlane SI. Prevention of Type 2 Diabetes: Evidence from Clinical Trials. Diabetes and Hypertension 2012. [DOI: 10.1007/978-1-60327-357-2_12] [Reference Citation Analysis]
82 Seguí Díaz M, Mediavilla Bravo J, Comas Samper J, Barquilla García A, Carramiñana Barrera F. Prevención de la diabetes mellitus 2. SEMERGEN - Medicina de Familia 2011;37:496-503. [DOI: 10.1016/j.semerg.2011.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 2011;34:1601-4. [PMID: 21709296 DOI: 10.2337/dc11-0046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
84 Kahn SE, Utzschneider KM. What's next for diabetes prevention? Diabetes Care 2011;34:1678-80. [PMID: 21709302 DOI: 10.2337/dc11-0694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
85 Hanefeld M, Schaper F. Drug therapy for the prevention of type 2 diabetes – is there a medical rationale? Diabetes & Vascular Disease 2011;11:168-74. [DOI: 10.1177/1474651411403987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
86 Díez Espino J. Prevención de la diabetes tipo 2 mediante el tratamiento farmacológico con pioglitazona en personas con intolerancia a la glucosa. FMC - Formación Médica Continuada en Atención Primaria 2011;18:461-462. [DOI: 10.1016/s1134-2072(11)70181-5] [Reference Citation Analysis]
87 DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34 Suppl 2:S202-9. [PMID: 21525456 DOI: 10.2337/dc11-s221] [Cited by in Crossref: 94] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
88 Tripathy D, Defronzo RA. Can we prevent diabetes with a single pill? Diabetes Management 2011;1:355-358. [DOI: 10.2217/dmt.11.35] [Reference Citation Analysis]
89 Stumvoll M, Tönjes A. Typ-2-Diabetes. Diabetologe 2011;7:179-193. [DOI: 10.1007/s11428-011-0684-1] [Reference Citation Analysis]
90 Souto SB, Souto EB, Braga DC, Medina JL. Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol 2011;67:653-61. [PMID: 21468743 DOI: 10.1007/s00228-011-1038-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
91 Damen J, Krul M. Moeten we prediabetes behandelen? HUISARTS WETENSCHAP 2011;54:54-55. [DOI: 10.1007/s12445-011-0036-9] [Reference Citation Analysis]
92 Dungan J. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Yearbook of Obstetrics, Gynecology and Women's Health 2011;2011:15-16. [DOI: 10.1016/j.yobg.2011.05.175] [Reference Citation Analysis]
93 Berne C, Campbell IW. Metformin is the lifelong partner in diabetes management: true or false? Diabetes & Vascular Disease 2011;11:42-51. [DOI: 10.1177/1474651410397255] [Reference Citation Analysis]
94 Westerhaus B, Gosmanov AR, Umpierrez GE. Diabetes prevention: can insulin secretagogues do the job? Prim Care Diabetes 2011;5:73-80. [PMID: 21185798 DOI: 10.1016/j.pcd.2010.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
95 Ferrante G, Zavalloni D, Corrada E, Presbitero P. Rosiglitazone plus metformin to prevent type 2 diabetes mellitus. The Lancet 2010;376:1387-1388. [DOI: 10.1016/s0140-6736(10)61948-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
96 &NA;. Low-dose combination better than placebo in delaying onset of diabetes in adults. Journal of the American Academy of Physician Assistants 2010;23:58. [DOI: 10.1097/01720610-201010000-00014] [Reference Citation Analysis]
97 Verner Codoceo R. Prevención de diabetes mellitus 2. Revista Médica Clínica Las Condes 2010;21:741-748. [DOI: 10.1016/s0716-8640(10)70595-2] [Reference Citation Analysis]
98 . Journal of Diabetes NEWS: Diabetes News. Journal of Diabetes 2010;2:130-5. [DOI: 10.1111/j.1753-0407.2010.00084.x] [Reference Citation Analysis]